ASCO Abstracts: Bristol-Myers Squibb's and Merck's Immuno-Oncology Drugs

Before you go, we thought you'd like these...
Before you go close icon

The American Society for Clinical Oncology annual meeting starts at the end of the month, but investors will get a peek at the immuno-oncology drugs to be highlighted at the meeting when the abstracts are released at 5 p.m. Eastern on Wednesday.

In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the PD-1 inhibitors, including Bristol-Myers Squibb's nivolumab and Merck's MK-3475, which are initially being tested in melanoma, but will likely be expanded into other solid tumors.

At ASCO, you can expect to see long-term data for nivolumab in combination with Bristol-Myers Squibb's Yervoy in melanoma patients, and Merck's MK-3475 in patients that have already failed Yervoy. Merck has already applied to the Food and Drug Administration for that indication, so the data should help investors identify any red flags that might disrupt an eventual approval.

Developing drugs is only half the business; good drugmakers have cash to pay investors with dividends
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

The article ASCO Abstracts: Bristol-Myers Squibb's and Merck's Immuno-Oncology Drugs originally appeared on

Brian Orelli has no position in any stocks mentioned. David Williamson owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading